Quanterix Announces the Simoa Accelerator

Published on: 

Applied Clinical Trials

Quanterix announced the opening of The Simoa Accelerator.

Quanterix Corporation, a provider of  high definition diagnostics, delivering ultrasensitive single molecule measurement, announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay development and clinical sample testing. Designed to provide access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, this state-of-the-art facility allows life science researchers to  explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology and other fields of medicine. 

 

Advertisement

Read the full release here.